← TG THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $323k |
$294k
-8.84%
|
$152k
-48.38%
|
$152k
0.00%
|
$152k
0.00%
|
$6.7m
+4300.66%
|
$2.8m
-58.36%
|
$233.7m
+8290.02%
|
$329.0m
+40.80%
|
$616.3m
+87.32%
|
$799.5m
+29.73%
|
|
| Cost of Revenue | $74.2m |
$113.0m
+52.32%
|
$166.7m
+47.54%
|
$159.7m
-4.19%
|
$232.2m
+45.41%
|
$790k
-99.66%
|
$265k
-66.46%
|
$14.1m
+5232.45%
|
$38.5m
+172.35%
|
$100.7m
+161.69%
|
$140.9m
+39.94%
|
|
| Gross Profit (Calculated) (derived) | ($73.8m) |
($112.7m)
-52.58%
|
($166.5m)
-47.79%
|
($159.6m)
+4.19%
|
($232.1m)
-45.45%
|
$5.9m
+102.54%
|
$2.5m
-57.28%
|
$219.5m
+8611.55%
|
$290.5m
+32.34%
|
$515.6m
+77.47%
|
— | |
| Research and Development Expense | $69.2m | $102.5m | $159.4m | $154.2m | $165.9m | $222.6m | $125.4m | $76.2m | $94.3m | $160.2m | $225.8m | |
| Selling, General and Administrative Expense | $5.1m | $6.0m | $7.9m | $9.5m | $41.5m | $128.1m | $70.0m | $122.7m | $154.3m | $232.0m | $296.5m | |
| Amortization of Intangible Assets | — | — | — | — | — | $212k | $212k | — | — | — | — | |
| Operating Lease, Expense | — | — | — | — | $2.7m | $2.2m | $2.7m | $2.2m | — | — | — | |
| Operating Expenses | $79.1m | $118.9m | $174.6m | $169.2m | $273.7m | $351.5m | $195.6m | — | — | — | $663.2m | |
| Operating Income (Loss) | ($79.0m) |
($118.7m)
-50.33%
|
($174.4m)
-46.91%
|
($169.1m)
+3.06%
|
($273.6m)
-61.84%
|
($344.8m)
-26.02%
|
($192.8m)
+44.07%
|
$20.6m
+110.70%
|
$41.9m
+103.21%
|
$123.3m
+194.13%
|
$136.3m
+10.54%
|
|
| Interest Income, Other | $323k | $294k | $857k | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | $5.0m | $7.7m | $10.8m | — | |
| Interest Expense (non-operating) | — | $845k | $877k | $5.3m | $6.3m | $5.6m | $10.2m | $12.6m | $24.0m | $26.7m | $37.5m | |
| Other Income | $393k | ($59k) | $61k | $1.5m | $542k | $2.3m | $4.7m | ($5.0m) | ($7.7m) | ($10.8m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $107.7m | $101.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | ($348.1m) | ($198.3m) | $13.1m | $25.6m | $107.4m | $101.6m | |
| Current Income Tax Expense (Benefit) | — | — | — | $0 | $0 | $0 | $0 | $400k | $2.2m | $8.2m | ($339.9m) | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $390k | $2.2m | ($339.8m) | ($339.9m) | |
| Net Income (Loss) Attributable to Parent | — | — | — | — | — | ($348.1m) |
($198.3m)
+43.02%
|
$12.7m
+106.39%
|
$23.4m
+84.52%
|
$447.2m
+1812.41%
|
$441.5m
-1.27%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($2.42) | ($2.63) | ($1.46) | $0.09 | $0.16 | $3.10 | $3.06 | |
| Earnings Per Share, Diluted | ($1.60) | ($1.91) | ($2.30) | ($1.96) | ($2.42) | ($2.63) | ($1.46) | $0.09 | $0.15 | $2.77 | $2.74 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | — | 135.4m | 142.0m | 145.3m | 144.3m | 142.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | — | 135.4m | 148.5m | 160.3m | 161.4m | 159.5m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | — | — | — | — | $213.0m | $287.1m | $493.0m | — | |
| Goodwill, Impairment Loss | — | — | — | $0 | $0 | $0 | $0 | $400k | $2.2m | $8.2m | — |